<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814069</url>
  </required_header>
  <id_info>
    <org_study_id>2021HNRT01</org_study_id>
    <nct_id>NCT04814069</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study</brief_title>
  <official_title>A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether concurrent Tislelizumab with postoperative chemoradiotherapy would&#xD;
      have survival benefit in high Risk HNSCC Patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year disease free survival</measure>
    <time_frame>1 year</time_frame>
    <description>from date of enrollment until date of first documented disease progression or from date of enrollment until date of first documented disease progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>from date of enrollment until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related acute toxicity as assessed weekly by CTCAE v4.0 during the course of treatment</measure>
    <time_frame>up to 3 months after completion of radiotherapy</time_frame>
    <description>Acute toxicity profiles, graded according to the NCI CTCAE version 4.0</description>
  </secondary_outcome>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Radiation</condition>
  <condition>PD-1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab 200mg q3w</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed squamous cell carcinoma of the head and neck. Site of tumor&#xD;
             origin in the oral cavity, oropharynx (p16-), larynx, or hypopharynx&#xD;
&#xD;
          2. With at least one high risk factor after radical surgery ①positive margin; ②close&#xD;
             margin（&lt;5mm); ③ENE.&#xD;
&#xD;
          3. No distant metastases&#xD;
&#xD;
          4. No synchronous or concurrent head and neck primary tumors&#xD;
&#xD;
          5. ECOG PS 0-1&#xD;
&#xD;
          6. Adequate organ function including the following:&#xD;
&#xD;
        Absolute neutrophil count (ANC) &gt;= 1.5 * 10^9/l Platelets count &gt;= 80 * 10^9/l Hemoglobin&#xD;
        &gt;= 80 g/dl AST and ALT &lt;= 2.5 times institutional upper limit of normal (ULN) Total&#xD;
        bilirubin &lt;= 1.5 times institutional ULN Creatinine clearance &gt;30 ml/min 8. Signed written&#xD;
        informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior&#xD;
             radiotherapy to the head and neck region&#xD;
&#xD;
          2. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell&#xD;
             carcinoma&#xD;
&#xD;
          3. Pregnant or breast-feeding females, or females and males of childbearing potential not&#xD;
             taking adequate contraceptive measures&#xD;
&#xD;
          4. Uncontrolled concomitant illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac&#xD;
             arrhythmia&#xD;
&#xD;
          5. Active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis,&#xD;
             Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I&#xD;
             diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin&#xD;
             disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment&#xD;
&#xD;
          6. Using systemic immunosuppressive agents and continue the dose within 2 weeks prior to&#xD;
             the enrollment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</investigator_affiliation>
    <investigator_full_name>Guopei Zhu</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

